BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686-693. [PMID: 22906998 DOI: 10.1016/j.cyto.2012.07.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Guo H, Li P, Su L, Wu K, Huang K, Lai R, Xu J, Sun D, Li S, Deng Z, Wang Y, Guo H, Chen Z, Wang S. Low expression of IL-37 protein is correlated with high Oct4 protein expression in hepatocellular carcinoma. Gene 2020;737:144445. [PMID: 32035244 DOI: 10.1016/j.gene.2020.144445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89:129-139. [PMID: 24029605 DOI: 10.1016/j.critrevonc.2013.08.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
3 Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 2019;129:3324-38. [PMID: 31305264 DOI: 10.1172/JCI126022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 37.0] [Reference Citation Analysis]
4 Choi J, Lee EJ, Yang SH, Im YR, Seong J. A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers. J Radiat Res 2019;60:242-8. [PMID: 30445597 DOI: 10.1093/jrr/rry092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang J, Pan Y, Ding Z, Yang G, Tan Y, Yang C, Jiang T, Liu L, Zhang B, Han T, Cao D, Yang T, Yang N, Wu M, Dong L, Wang H. RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription. Oncogene 2015;34:1575-83. [DOI: 10.1038/onc.2014.84] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gelu-Simeon M, Samuel D. Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. Hepatol Int 2013;7:788-91. [PMID: 26201913 DOI: 10.1007/s12072-013-9441-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Zhao X, Luo J, Li B, Liu S, Li D. The association between preoperative serum C-reactive protein and hepatocellular carcinoma recurrence in patients with chronic hepatitis B virus (HBV) infection--a retrospective study. PLoS One. 2015;10:e0116909. [PMID: 25602444 DOI: 10.1371/journal.pone.0116909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Wang F, Sun NN, Li LL, Zhu WW, Xiu J, Shen Y, Xu Q. Hepatic progenitor cell activation is induced by the depletion of the gut microbiome in mice. Microbiologyopen 2019;8:e873. [PMID: 31094067 DOI: 10.1002/mbo3.873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li YX, Ren YL, Fu HJ, Zou L, Yang Y, Chen Z. Hepatitis B Virus Middle Protein Enhances IL-6 Production via p38 MAPK/NF-κB Pathways in an ER Stress-Dependent Manner. PLoS One 2016;11:e0159089. [PMID: 27434097 DOI: 10.1371/journal.pone.0159089] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
10 Pang S, Zhou Z, Yu X, Wei S, Chen Q, Nie S, Liang X, Liu L. The predictive value of integrated inflammation scores in the survival of patients with resected hepatocellular carcinoma: A Retrospective Cohort Study. Int J Surg 2017;42:170-7. [PMID: 28414120 DOI: 10.1016/j.ijsu.2017.04.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
11 Hu L, Zhu Y, Zhang J, Chen W, Li Z, Li L, Zhang L, Cao D. Potential circulating biomarkers of circulating chemokines CCL5, MIP-1β and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection. BMC Infect Dis 2019;19:523. [PMID: 31200663 DOI: 10.1186/s12879-019-4130-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
12 Le Y, Shen JX, Zhang YF, He MK, Kan A, Chen HL, Yu ZS, Li QJ, Shi M. Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. J Cancer 2019;10:665-71. [PMID: 30719164 DOI: 10.7150/jca.28528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Khattab M, Fouad M, Ahmed E. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol 2015;7:2474-81. [PMID: 26483869 DOI: 10.4254/wjh.v7.i23.2474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Han NI, Yoon SK. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019;9:3260. [PMID: 30824840 DOI: 10.1038/s41598-019-40078-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
15 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Kornberg A, Witt U, Kornberg J, Müller K, Friess H, Thrum K. Postoperative peak serum C-reactive protein is a predictor of outcome following liver transplantation for hepatocellular carcinoma. Biomarkers 2016;21:152-9. [PMID: 26643974 DOI: 10.3109/1354750X.2015.1118548] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, Tang NLS, Lee KF, Lai PBS, Yu SCH, Yeo W. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:2719-27. [PMID: 31040713 DOI: 10.2147/CMAR.S178482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:182-90. [PMID: 30324143 DOI: 10.5114/ceh.2018.78122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
19 Talaat RM, Salem TA, El-masry S, Imbarek A, Mokhles M, Abdel-aziz A. Circulating pro- and anti-angiogenic mediators in patients infected with hepatitis C at different stages of hepatocellular carcinoma: Angiogenesis in HCC Patients. J Med Virol 2014;86:1120-9. [DOI: 10.1002/jmv.23932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, Lee S, Bae SH. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol 2015;15:146. [PMID: 26498833 DOI: 10.1186/s12876-015-0378-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
21 Liu YC, Wu RH, Wang WS. Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-κB inactivation in SK-Hep1 cells. Oncol Lett 2017;14:461-7. [PMID: 28693192 DOI: 10.3892/ol.2017.6142] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
22 Liu YB, Ying J, Kuang SJ, Jin HS, Yin Z, Chang L, Yang H, Ou YL, Zheng JH, Zhang WD, Li CS, Jian ZX. Elevated Preoperative Serum Hs-CRP Level as a Prognostic Factor in Patients Who Underwent Resection for Hepatocellular Carcinoma. Medicine (Baltimore) 2015;94:e2209. [PMID: 26656354 DOI: 10.1097/MD.0000000000002209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
23 Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013;10:653-664. [PMID: 23569429 DOI: 10.7150/ijms.6050] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
24 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-78] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
25 Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto J, Furukawa T, Yamakita I, Kurokawa T, Okada M. Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer. World J Surg 2017;41:1558-65. [PMID: 28120093 DOI: 10.1007/s00268-017-3900-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
26 Wu Y, Fan W, Xue M, Zhong B, Zhang S, Wang Y, Yao W, Zhao Y, Li J. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Oncologist 2019;24:e1489-95. [PMID: 31249138 DOI: 10.1634/theoncologist.2018-0669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, Helferich WG, Heneberg P, Honoki K, Keith WN, Kerkar SP, Mohammed SI, Niccolai E, Nowsheen S, Vasantha Rupasinghe HP, Samadi A, Singh N, Talib WH, Venkateswaran V, Whelan RL, Yang X, Felsher DW. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015;35 Suppl:S199-S223. [PMID: 25865775 DOI: 10.1016/j.semcancer.2015.02.007] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 24.8] [Reference Citation Analysis]
28 Zhao Z, Xiong S, Wang R, Li Y, Wang X, Wang Y, Bai S, Chen W, Zhao Y, Cheng B. Peri-tumor fibroblasts promote tumorigenesis and metastasis of hepatocellular carcinoma via Interleukin6/STAT3 signaling pathway. Cancer Manag Res 2019;11:2889-901. [PMID: 31118769 DOI: 10.2147/CMAR.S192263] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015;356:114-25. [PMID: 23994343 DOI: 10.1016/j.canlet.2013.08.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
30 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282. [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
31 Sugimoto Y, Wakai K, Nakagawa H, Suma S, Sasakabe T, Sakamoto T, Takashima N, Suzuki S, Ogawa S, Ohnaka K, Kuriyama N, Arisawa K, Mikami H, Kubo M, Hosono S, Hamajima N, Tanaka H; J-MICC Study Group. Associations between polymorphisms of interleukin-6 and related cytokine genes and serum liver damage markers: a cross-sectional study in the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. Gene 2015;557:158-62. [PMID: 25523094 DOI: 10.1016/j.gene.2014.12.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
32 Chen VL, Le AK, Podlaha O, Estevez J, Li B, Vutien P, Chang ET, Rosenberg-Hasson Y, Pflanz S, Jiang Z, Ge D, Gaggar A, Nguyen MH. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. Sci Rep. 2017;7:11169. [PMID: 28894136 DOI: 10.1038/s41598-017-10498-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 Lee HL, Jang JW, Han JW, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Lee JW. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Dig Dis Sci 2019;64:2992-3000. [PMID: 30982209 DOI: 10.1007/s10620-019-05614-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Shakiba E, Sadeghi M, Shakiba M. A systematic review and meta-analysis of evaluation of serum interleukin 8 levels in hepatocellular carcinoma. Clin Exp Hepatol 2019;5:123-8. [PMID: 31508492 DOI: 10.5114/ceh.2019.84780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer 2016;5:257-68. [PMID: 27781198 DOI: 10.1159/000449337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
37 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
38 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
39 Santetti D, de Albuquerque Wilasco MI, Dornelles CT, Werlang IC, Fontella FU, Kieling CO, Dos Santos JL, Vieira SM, Goldani HA. Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease. World J Gastroenterol 2015;21:8927-34. [PMID: 26269683 DOI: 10.3748/wjg.v21.i29.8927] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Mori S, Kita J, Kato M, Shimoda M, Kubota K. Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy. Am J Surg 2015;209:187-93. [PMID: 24950991 DOI: 10.1016/j.amjsurg.2014.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, Jekarl DW, Lee S. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64:516-522. [PMID: 24035756 DOI: 10.1016/j.cyto.2013.07.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
42 Öcal O, Kupčinskas J, Morkunas E, Amthauer H, Schütte K, Malfertheiner P, Klümpen HJ, Sengel C, Benckert J, Seidensticker R, Sangro B, Wildgruber M, Pech M, Bartenstein P, Ricke J, Seidensticker M. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res 2021;11:51. [PMID: 34080071 DOI: 10.1186/s13550-021-00791-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F, Grassi G. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol. 2014;20:1268-1288. [PMID: 24574801 DOI: 10.3748/wjg.v20.i5.1268] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
44 Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi XS, Wang XL, Deng GL, Sun X. The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. Medicine (Baltimore). 2015;94:e941. [PMID: 26091457 DOI: 10.1097/MD.0000000000000941] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
45 Kern L, Mittenbühler MJ, Vesting AJ, Ostermann AL, Wunderlich CM, Wunderlich FT. Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation-Driven Liver and Colorectal Cancers. Cancers (Basel) 2018;11:E24. [PMID: 30591653 DOI: 10.3390/cancers11010024] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 16.7] [Reference Citation Analysis]
46 Qi Q, Bie P. Different roles of hepatic hypothermic ischemia and ischemic preconditioning in chemically induced hepatocarcinogenesis in rats. J Surg Res. 2014;189:213-221. [PMID: 24725680 DOI: 10.1016/j.jss.2014.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:1529-1535. [PMID: 25968302 DOI: 10.1111/jgh.13005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
48 Deng Y, Li M, Wang J, Xie L, Li T, He Y, Lu Q, Li R, Tan A, Qin X. Susceptibility to hepatocellular carcinoma in the Chinese population--associations with interleukin-6 receptor polymorphism. Tumour Biol. 2014;35:6383-6388. [PMID: 24668548 DOI: 10.1007/s13277-014-1863-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li C, Peng Y, Mao B, Qian K. Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget 2015;6:17792-804. [PMID: 25970775 DOI: 10.18632/oncotarget.3785] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
50 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 271] [Article Influence: 45.6] [Reference Citation Analysis]
51 Wang H, Liu J, Hu X, Liu S, He B. Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. Med Sci Monit 2016;22:3694-704. [PMID: 27739418 DOI: 10.12659/msm.899773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
52 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:35-40. [PMID: 29594196 DOI: 10.5114/ceh.2018.73484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Fujiwara N, Tateishi R, Nakagawa H, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Shiina S, Yoshida H, Koike K. Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma. Hepatol Res 2015;45:645-55. [PMID: 25070147 DOI: 10.1111/hepr.12398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
54 Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Shiina S, Yoshida H, Koike K. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. J Gastroenterol Hepatol 2015;30:379-88. [PMID: 25168107 DOI: 10.1111/jgh.12719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
55 Gu Y, Srimathveeravalli G, Cai L, Ueshima E, Maybody M, Yarmohammadi H, Zhu YS, Durack JC, Solomon SB, Coleman JA, Erinjeri JP. Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model. Cryobiology 2018;82:106-11. [PMID: 29621494 DOI: 10.1016/j.cryobiol.2018.03.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
57 Baranyai Z, Jósa V, Tóth A, Szilasi Z, Tihanyi B, Zaránd A, Harsanyi L, Szállási Z. Paraneoplastic thrombocytosis in gastrointestinal cancer. Platelets 2016;27:269-75. [PMID: 27136385 DOI: 10.3109/09537104.2016.1170112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
58 Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Sukowati CHC, Patti R, Pascut D, Ladju RB, Tarchi P, Zanotta N, Comar M, Tiribelli C, Crocè LS. Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma. Biomed Res Int 2018;2018:6435482. [PMID: 30246025 DOI: 10.1155/2018/6435482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
60 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. [PMID: 26879559 DOI: 10.1038/srep21260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]